Anna Kanerva
Impact in
Papers in
- Co-authors
- Akseli Hemminki (114 shared papers)David T. Curiel (18 shared papers)Gerd Johannes Bauerschmitz (22 shared papers)Vincenzo Cerullo (26 shared papers)Ronald David Alvarez (9 shared papers)Tanja Hakkarainen (16 shared papers)Riikka Havunen (27 shared papers)Merja Särkioja (17 shared papers)
- Journals
- Molecular Therapy (18 papers)International Journal of Cancer (11 papers)Gene Therapy (10 papers)OncoImmunology (8 papers)Cancer Gene Therapy (7 papers)
- Partner nations
- FinlandUnited StatesGermany
In The Last Decade
Anna Kanerva
122 papers receiving 4.8k citations
Peers
Comparison fields: 5 of 87
- Genetics 3.9k
- Oncology 2.9k
- Biotechnology 884
- Molecular Biology 2.3k
- Immunology 662
Countries citing papers authored by Anna Kanerva
This map shows the geographic impact of Anna Kanerva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Kanerva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Kanerva more than expected).
Fields of papers citing papers by Anna Kanerva
This network shows the impact of papers produced by Anna Kanerva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Kanerva. The network helps show where Anna Kanerva may publish in the future.
Co-authors
The 25 scholars most cited alongside Anna Kanerva, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 123 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. | 2002 | 214 |
| 2 | 2002 | 159 | |
| 3 | 2013 | 153 | |
| 4 | 2003 | 148 | |
| 5 | 2013 | 144 | |
| 6 | 2011 | 139 | |
| 7 | Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. | 2002 | 132 |
| 8 | 2007 | 124 | |
| 9 | 2012 | 117 | |
| 10 | 2004 | 113 | |
| 11 | 2017 | 106 | |
| 12 | 2018 | 96 | |
| 13 | 2003 | 90 | |
| 14 | Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. | 2003 | 89 |
| 15 | 2007 | 89 | |
| 16 | 2008 | 88 | |
| 17 | 2002 | 88 | |
| 18 | 2012 | 87 | |
| 19 | 2015 | 75 | |
| 20 | 2012 | 72 |
About Anna Kanerva
Anna Kanerva is a scholar working on Genetics, Oncology, Biotechnology, Molecular Biology and Immunology, having authored 123 papers that have together received 4.9k indexed citations. Recurring topics across this work include Virus-based gene therapy research (108 papers), CAR-T cell therapy research (76 papers), Viral Infectious Diseases and Gene Expression in Insects (31 papers), Cancer Research and Treatments (25 papers), RNA Interference and Gene Delivery (16 papers), Immunotherapy and Immune Responses (15 papers), Viral gastroenteritis research and epidemiology (7 papers) and Ovarian cancer diagnosis and treatment (4 papers). The work is most often cited by research in Genetics (3.9k citations), Oncology (2.9k citations), Biotechnology (884 citations), Molecular Biology (2.3k citations) and Immunology (662 citations). Anna Kanerva has collaborated with scholars based in Finland, United States and Germany. Frequent co-authors include Akseli Hemminki, David T. Curiel, Gerd Johannes Bauerschmitz, Vincenzo Cerullo, Ronald David Alvarez, Tanja Hakkarainen, Riikka Havunen, Merja Särkioja, Lotta Kangasniemi and Renée A. Desmond. Their work appears in journals such as Molecular Therapy, International Journal of Cancer, Gene Therapy, OncoImmunology and Cancer Gene Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.